Watanabe Hironobu, Enjoji Munechika, Nakashima Manabu, Noguchi Ken-ichi, Kinukawa Naoko, Sugimoto Rie, Kotoh Kazuhiro, Nakamuta Makoto, Nawata Hajime, Watanabe Takeshi
Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
J Hepatol. 2003 Oct;39(4):559-63. doi: 10.1016/s0168-8278(03)00363-5.
BACKGROUND/AIMS: The tumor-associated antigen, RCAS1, has been reported to be expressed in various types of cancer, including cholangiocarcinoma. We measured serum RCAS1 levels in patients with intrahepatic cholangiocellular carcinoma (CCC) and other hepatobiliary diseases, and examined the clinical significance of serum RCAS1 as a tumor marker.
Sera collected from the patients and healthy volunteers were used for ELISA for RCAS1. The values of RCAS1 for CCC patients were compared to those of other tumor marker proteins.
Serum RCAS1 levels exceeded the normal limit in a high percentage (73.9%) of CCC patients. The positivity rate was higher than those of CA19-9 and CEA. No correlation was found between the RCAS1 and CA19-9 concentrations. Serum RCAS1 was positive in many cases that were negative for CA19-9. Surgical resection of CCC reduced the RCAS1 level to within the normal range. On the other hand, serum RCAS1 levels were elevated in very few cases of benign hepatobiliary disease.
As a tumor marker in CCC, RCAS1 is, at least, of complementary value to CA19-9 and CEA. Measuring serum RCAS1 contributes to the diagnostic accuracy, and is useful for estimating tumor progression or therapeutic effect.
背景/目的：肿瘤相关抗原RCAS1已被报道在包括胆管癌在内的多种癌症类型中表达。我们检测了肝内胆管细胞癌（CCC）患者及其他肝胆疾病患者的血清RCAS1水平，并探讨了血清RCAS1作为肿瘤标志物的临床意义。
将患者和健康志愿者采集的血清用于RCAS1的酶联免疫吸附测定（ELISA）。将CCC患者的RCAS1值与其他肿瘤标志物蛋白的值进行比较。
在高比例（73.9%）的CCC患者中，血清RCAS1水平超过正常范围。其阳性率高于CA19-9和癌胚抗原（CEA）。未发现RCAS1与CA19-9浓度之间存在相关性。在许多CA19-9阴性的病例中，血清RCAS1呈阳性。CCC手术切除后，RCAS1水平降至正常范围内。另一方面，在极少数良性肝胆疾病病例中，血清RCAS1水平升高。
作为CCC的肿瘤标志物，RCAS1至少与CA19-9和CEA具有互补价值。检测血清RCAS1有助于提高诊断准确性，并有助于评估肿瘤进展或治疗效果。
